Browse
Submit Data
Databases
API
Help

Dataset Information

6 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of by comparing human breast cancer cell line MDA-MB-468 cyclin E transfected cells with control-transfected cells vs a control

ABSTRACT: We studied the effect of cyclin E overexpression in the breast cancer cell line MDA-MB-468, by comparing cyclin E transfected cells with control-transfected cells. The cyclin E/control hybridization was performed twice and cDNA from control transfected cells was used as a reference.

ORGANISM(S): Homo sapiens

SUBMITTER: Berglund P

PROVIDER: S-ECPF-MEXP-339 | biostudies-other | 2005 Nov

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of by comparing human breast cancer cell line MDA-MB-468 cyclin E transfected cells with control-transfected cells vs a control

Project description:We studied the effect of cyclin E overexpression in the breast cancer cell line MDA-MB-468, by comparing cyclin E transfected cells with control-transfected cells. The cyclin E/control hybridization was performed twice and cDNA from control transfected cells was used as a reference.

2005-05-31 | E-MEXP-339 | biostudies-arrayexpress

Transcription profiling of human rapamycin treated of MDA-MB-468 breast cancer cell line and MDA-MB-468 xenografts

Project description: Not available

| S-ECPF-GEOD-18571 | biostudies-other

Breast cancer MCF-7 Cells and MDA-MB-435 cells: pre-miR-125b Transfected cells vs. pre-control transfected cells

Project description: Not available

| S-ECPF-GEOD-22546 | biostudies-other

Breast cancer MCF-7 cells and MDA-MB-231 cells: LNA-antimiR-21 transfected cells vs. LNA-control transfected cells

Project description: Not available

| S-ECPF-GEOD-20627 | biostudies-other

ALDH1A3-mediated gene expression in MDA-MB-231 cells and MDA-MB-468 cells

Project description: Not available

| S-ECPF-GEOD-49322 | biostudies-other

Progesterone signals through membrane progesterone receptors (mPRs) in MDA-MB-468 and mPR-transfected MDA-MB-231 breast cancer cells which lack full-length and N-terminally truncated isoforms of the nuclear progesterone receptor.

Project description: Not available

| S-EPMC3129471 | biostudies-literature

Rapamycin treatment of MDA-MB-468 breast cancer cell line and MDA-MB-468 xenografts

Project description:Mammalian target of rapamycin (mTOR) is a serine/threonine kinase involved in multiple intracellular signaling pathways promoting tumor growth. mTOR is aberrantly activated in a significant portion of breast cancers and is a promising target for treatment. Rapamycin and its analogues are in clinical trials for breast cancer treatment. Patterns of gene expression (metagenes) may also be used to simulate a biologic process of effects of a drug treatment. In this study, we tested the hypothesis that the gene-expression signature regulated by rapamycin could predict disease outcome for patients with breast cancer. Results: Colony formation and sulforhodamine B (IC50 < 1nM) assays, and xenograft animals showed that MDA-MB-468 cells were sensitive to treatment with rapamycin. The comparison of in vitro and in vivo gene expression data identified a signature, termed rapamycin metagene index (RMI), of 31 genes upregulated by rapamycin treatment in vitro as well as in vivo (false discovery rate of 10%). In the Miller dataset, RMI was significantly associated with tumor size or lymph node status. High (>75) percentile) RMI was significantly associated with longer survival (P = 0.015). On multivariate analysis, RMI (P = 0.029), tumor size (P = 0.015) and lymph node status (P = 0.01) were prognostic. In van 't Veer study, RMI was not associated with the time to develop distant metastasis (P = 0.41). In Wang dataset, RMI predicted time to disease relapse (P = 0.09). Conclusions: Rapamycin-regulated gene expression signature predicts clinical outcome in breast cancer. This supports the central role of mTOR signaling in breast cancer biology and provides further impetus to pursue mTOR-targeted therapies for breast cancer treatment. Mol Cancer. 2009 Sep 24;8(1):75.

2009-11-20 | GSE18571 | GEO

MDA-MB-231 cells: shMUC4 transfected vs. Control SCR

Project description:Identification of MUC4-associated expression of genes by comparing MUC4 knockdown (MDA-MB-231-shMUC4) and control (MDA-MB-231-SCR).

2012-12-31 | GSE40157 | GEO

Overexpressing modified human TR?1 suppresses the proliferation of breast cancer MDA-MB-468 cells.

Project description: Not available

| S-EPMC6019938 | biostudies-literature

<i>β-catenin</i> knockdown enhances the effects of fluorouracil in the breast cancer cell line MDA-MB-468.

Project description: Not available

| S-EPMC4179739 | biostudies-literature